Building the Case for New Complicated UTI Treatments

In "Building the Case for New Complicated UTI Treatments," the panel builds the practical case for getting a promising new complicated UTI agent onto formulary and into real use.

Returning to Dr. Pogue, Dr. Gupta asks how clinicians should weigh a newer therapy's higher upfront cost against potential downstream savings like avoiding complications or readmissions. Dr. Pogue describes three requirements he has seen shape successful adoption over his career. First is unmet need, echoing Dr. Kaye's earlier point that a drug must do something existing options cannot. Second is the ability to cost-justify the agent, whether by avoiding hospitalization entirely or by shortening an admission that would otherwise require intravenous access. Third, and most often overlooked, is an institutional champion willing to drive implementation, since inertia otherwise prevails. Dr. Pogue points to long-acting antibiotics in skin infection as a blueprint for hitting all three criteria, contrasting that success with the slower uptake of oral linezolid and fidaxomicin. Dr. Gupta then asks Dr. Nelson about prior authorization barriers for newer therapies. Dr. Nelson describes prior authorization as a persistent, time-intensive burden that many health systems now staff with dedicated, often non-billable teams. He sees momentum building toward electronic prior authorization processes. Those processes could replace time-consuming payer phone calls that currently pull clinicians away from patient care. He suggests modeling or artificial intelligence could eventually help calculate cost differences between staying on current regimens and switching therapies. Closing the segment, Dr. Gupta asks Dr. Kaye what policy or protocol changes would help streamline this landscape. Dr. Kaye emphasizes that clinicians need awareness of which new antimicrobials exist and where they fit, citing early misconceptions about ertapenem's activity against Pseudomonas as a cautionary example. He stresses that a new drug on formulary accomplishes nothing without stewardship infrastructure, microbiology lab support, and floor-level champions, plus published examples of how other health systems successfully implemented similar changes. As Dr. Gupta summarizes, optimizing complicated UTI care is, ultimately, a team sport.

In "IDSA's New Complicated UTI Guideline: Definitions and Rationale," the panel shifts from cost and access to the clinical definitions driving complicated UTI care.